An Early Feasibility, Prospective, Single-Arm Study of the Polaris System

NCT ID: NCT06990074

Last Updated: 2026-01-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-09-23

Study Completion Date

2026-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A multicenter, single-arm, prospective, non-randomized, non-masked study.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study aims to assess the safety of the Polaris System in assisting surgeons to perform cataract surgery.

The Polaris System is intended to enhance precision and safety over the current standard of care by employing improved stability controls and augmented visualization properties, enabling safer surgical decisions and finer control of surgical instruments.

This study will be conducted at up to 3 research sites. After the informed consent process, potential participants will be considered enrolled in the study and undergo the screening evaluation. Following confirmation of eligibility, selected participants will be sequentially assigned to undergo robot-assisted cataract surgery and receive four scheduled follow-ups over 90 days, post-intervention.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cataract, Age-Related

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants with age-related uncomplicated cataract

Single eye cataract robot-assisted cataract surgery.

Participants will receive intraoperative eye preparation according to the standard of care for cataract surgery. Under general anesthesia, a docking procedure between the study eye and the medical device will be completed. The surgeon will use the Polaris System to perform initial surgical tasks and perform the initial portion of the affected lens extraction. Finally, the surgeon will use the Polaris System to complete the lens extraction and perform the final surgical tasks, including the intraocular lens implantation.

Group Type EXPERIMENTAL

cataract surgery

Intervention Type DEVICE

Robot-assisted cataract surgery

cataract surgery

Intervention Type DEVICE

Robot-assisted cataract surgery, designed to provide superior precision and increase the safety profile of the current standard of care.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

cataract surgery

Robot-assisted cataract surgery

Intervention Type DEVICE

cataract surgery

Robot-assisted cataract surgery, designed to provide superior precision and increase the safety profile of the current standard of care.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female, between 40 and 75 (inclusive) years of age (measured at baseline)
* A slit-lamp diagnosis of uncomplicated, age-related visually significant cataract that is not posterior polar or congenital
* Eligible to undergo cataract extraction by phacoemulsification with intraocular lens (IOL) implantation
* Able and willing to comply with all study procedures
* Able to return for scheduled follow-up examinations
* Willing to adhere to the prescribed medication regimen (to prevent inflammation and infection)
* Provision of signed and dated informed consent form

Exclusion Criteria

* Contraindication to general anesthesia
* Posterior polar or congenital cataract
* Previous history of vitrectomy, corneal, refractive, or cataract surgery
* Concurrent participation in another ophthalmological clinical study
* Allergies to any medications required in surgery, pre- and post-operative treatment
* Diagnosis of corneal disease or pathology that precludestransmission of optical coherence tomography (OCT) laser wavelength (e.g., corneal opacity), distorts OCT laser light (e.g., corneal scarring or history of radial keratotomy), or compromises engagement of the patient interface (e.g., megalocornea or pterygium), in the opinion of the Investigator
* History of poor pupil dilation, demonstration of poor reaction to pupil-dilation drugs (minimum 7 mm dilation should be targeted for study), diagnosis of a pupillary defect that precludes the iris from adequate peripheral retraction, and/or diagnosis of floppy iris syndrome or iris dyscoria
* Current or prior use of concomitant medications known to cause floppy iris syndrome (e.g., alpha-blockers, such as Flomax)
* Compromised cornea (e.g., Fuchs endothelial dystrophy)
* History of lens or zonular instability
* Immunocompromised or diagnosis of ophthalmic disease: ocular herpes zoster or simplex, lupus, collagenosis or other acute or chronic illnesses that increase the risk to the subject or confounds the outcomes of this study, in the opinion of the Investigator
* Developmental disability or cognitive impairment that would make informed consent and the assessment of visual acuity impossible, in the opinion of the Investigator
* History of significant ocular trauma
* History of iritis or uveitis
* Pregnant women, as confirmed via urine pregnancy test for women of child-bearing age at screening
Minimum Eligible Age

40 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Horizon Surgical Systems Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinica Quesada SA de CV

San Salvador, San Salvador Department, El Salvador

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

El Salvador

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Pooria Kashani Vice-president of Product

Role: CONTACT

908-477-8382

Jean-Pierre Hubschman, Chief Executive Officer

Role: CONTACT

310-691-9061

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Gabriel Quesada

Role: primary

+503-6184-6996

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HS-001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Cataract Surgery Clinical Trial
NCT07044674 WITHDRAWN NA
Photopic and Mesopic Multifocal IOL Performance
NCT06978556 ACTIVE_NOT_RECRUITING